Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pds Biotechnology Corp (PDSB)

Pds Biotechnology Corp (PDSB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 31,686
  • Shares Outstanding, K 52,374
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,610 K
  • EBIT $ -32 M
  • EBITDA $ -31 M
  • 60-Month Beta 1.20
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.82
  • Most Recent Earnings $-0.19 on 11/13/25
  • Next Earnings Date 05/13/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 340.57% (-145.62%)
  • Historical Volatility 93.91%
  • IV Percentile 51%
  • IV Rank 24.29%
  • IV High 1,204.24% on 12/02/25
  • IV Low 63.55% on 12/16/25
  • Expected Move (DTE 16) 0.0425 (7.02%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 64
  • Put/Call OI Ratio 0.02
  • Today's Open Interest 2,567
  • Open Int (30-Day) 2,119
  • Expected Range 0.5626 to 0.6476

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.15
  • Number of Estimates 1
  • High Estimate $-0.15
  • Low Estimate $-0.15
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) +28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5068 +18.53%
on 03/31/26
0.7349 -18.26%
on 03/17/26
-0.0743 (-11.01%)
since 02/27/26
3-Month
0.5068 +18.53%
on 03/31/26
1.1500 -47.77%
on 01/09/26
-0.1691 (-21.97%)
since 12/31/25
52-Week
0.5068 +18.53%
on 03/31/26
1.9150 -68.63%
on 06/11/25
-0.4793 (-44.38%)
since 04/01/25

Most Recent Stories

More News
PDS Biotechnology: Q4 Earnings Snapshot

PDS Biotechnology: Q4 Earnings Snapshot

PDSB : 0.6001 (-0.81%)
PDS Biotech Reports Full Year 2025 Financial Results and Provides Update on PDS0101 Phase 3 Program and PDS01ADC Clinical Advancement

Filed Phase 3 Amendment Incorporates PFS as Interim Primary Endpoint Expected to Shorten Trial Duration and Reduce Costs Conference Call and Webcast Today at 8:00 am Eastern Time PRINCETON,...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces Conference Call and Webcast for 2025 Fourth Quarter and Year End Financial Results

PRINCETON, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces Adoption of Amended Protocol for Phase 3 VERSATILE-003 Trial Incorporating Progression Free Survival (PFS) as Primary Endpoint for Interim Analysis and Potential Accelerated Approval

PRINCETON, N.J., Feb. 20, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI

NCI-Led Study Shows Median PFS of 9.6 Months  Results Presented at AACR Special Conference on Innovations in Prostate Cancer PRINCETON, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101

PRINCETON, N.J., Jan. 22, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 ...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan

New Patent Grants Broad Composition Claims for PDS0101 Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040s ...

PDSB : 0.6001 (-0.81%)
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)

PRINCETON, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how...

PDSB : 0.6001 (-0.81%)
PDS Biotechnology: Q3 Earnings Snapshot

PDS Biotechnology: Q3 Earnings Snapshot

PDSB : 0.6001 (-0.81%)

Business Summary

PDS Biotechnology Corp. is an immuno-oncology company. It is focused on developing a pipeline of clinical-stage immunotherapies to treat cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, cancer and other cancers. The company's products are based on the proprietary...

See More

Key Turning Points

3rd Resistance Point 0.7359
2nd Resistance Point 0.6705
1st Resistance Point 0.6377
Last Price 0.6001
1st Support Level 0.5395
2nd Support Level 0.4741
3rd Support Level 0.4413

See More

52-Week High 1.9150
Fibonacci 61.8% 1.3771
Fibonacci 50% 1.2109
Fibonacci 38.2% 1.0447
Last Price 0.6001
52-Week Low 0.5068

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.